We’re advancing next-gen multi-payload ADCs with unique payload and linker tech to deliver dual agents to tumor cells, maximizing benefits for cancer patients.
Callio Therapeutics raises $187M Series A for cancer ADCs
Callio Therapeutics raised $187M in Series A funding for multi-payload antibody-drug conjugates to improve cancer therapy, led by Frazier Life Sciences with other investors.
Callio Therapeutics launches with $187M Series A funding
Callio Therapeutics launches with $187M Series A funding to develop multi-payload antibody-drug conjugates for cancer therapy, based on technology from Hummingbird Bioscience.
Callio Therapeutics launches with $187M Series A funding
Callio Therapeutics launches with $187M Series A funding, focusing on multi-payload ADCs for cancer treatment. Led by Frazier Life Sciences with other investors participating.
JPMorgan: Crypto Market Structure Act likely to pass mid-year
JPMorgan predicts the Crypto Market Structure Act will likely pass by mid-2026, potentially transforming the crypto market and attracting institutional investors.